Al Meslamani AZ - Search Results

1

Navigating the crossroads: asthma, trained immunity, and infection susceptibility.

Al Meslamani AZ, Merghani Ali E. Al Meslamani AZ, et al. Expert Rev Clin Immunol. 2024 May 8. doi: 10.1080/1744666X.2024.2353743. Online ahead of print. Expert Rev Clin Immunol. 2024. PMID: 38716705 No abstract available.

2

Beyond resistance: assessing sulbactam-Durlobactam's role in Today's clinical landscape.

Al Meslamani AZ. Al Meslamani AZ. Expert Rev Anti Infect Ther. 2024 May 2. doi: 10.1080/14787210.2024.2351026. Online ahead of print. Expert Rev Anti Infect Ther. 2024. PMID: 38697811 No abstract available.

3

Barriers to transforming community pharmacies into point-of-care testing sites in low- and middle-income countries.

Jarab AS, Abu Heshmeh SR, Al Meslamani AZ. Jarab AS, et al. Among authors: al meslamani az. Int J Pharm Pract. 2024 May 7;32(3):256-258. doi: 10.1093/ijpp/riae011. Int J Pharm Pract. 2024. PMID: 38558133 No abstract available.

4

Adverse drug event reporting among women: uncovering disparities in underserved communities.

Al Meslamani AZ. Al Meslamani AZ. Expert Opin Drug Saf. 2024 Mar 30:1-3. doi: 10.1080/14740338.2024.2337745. Online ahead of print. Expert Opin Drug Saf. 2024. PMID: 38551021 No abstract available.

5

Assessing the economic impact of digital endpoints on medication adherence.

Al Meslamani AZ, Li N. Al Meslamani AZ, et al. Expert Rev Pharmacoecon Outcomes Res. 2024 Mar 25:1-3. doi: 10.1080/14737167.2024.2334893. Online ahead of print. Expert Rev Pharmacoecon Outcomes Res. 2024. PMID: 38520281 No abstract available.

6

Barriers to digital endpoints in data collection in low and middle-income countries.

Al Meslamani AZ. Al Meslamani AZ. Expert Rev Pharmacoecon Outcomes Res. 2024 Mar 18:1-3. doi: 10.1080/14737167.2024.2331047. Online ahead of print. Expert Rev Pharmacoecon Outcomes Res. 2024. PMID: 38480011 No abstract available.

7

Disparities in drug safety practices in developing nations: focusing on underlying factors and implications for global health.

Al Meslamani AZ, Abdel-Qader DH, Kassem AB, Al Mazrouei N. Al Meslamani AZ, et al. Expert Opin Drug Saf. 2024 Apr;23(4):393-397. doi: 10.1080/14740338.2024.2326488. Epub 2024 Mar 7. Expert Opin Drug Saf. 2024. PMID: 38436276 No abstract available.

8

Examining the impact of biosimilar-to-biosimilar transition on effectiveness and safety.

Jarab AS, Abu Heshmeh SR, Al Meslamani AZ. Jarab AS, et al. Among authors: al meslamani az. Expert Opin Biol Ther. 2024 Feb 28:1-4. doi: 10.1080/14712598.2024.2324123. Online ahead of print. Expert Opin Biol Ther. 2024. PMID: 38404241 No abstract available.

9

Antiretroviral therapy response: exploring the potential influence of SARS-CoV-2.

Al Meslamani AZ. Al Meslamani AZ. Expert Rev Clin Pharmacol. 2024 Feb 28:1-4. doi: 10.1080/17512433.2024.2322984. Online ahead of print. Expert Rev Clin Pharmacol. 2024. PMID: 38390721 No abstract available.

10

Insights into artificial intelligence utilisation in drug discovery.

Abou Hajal A, Al Meslamani AZ. Abou Hajal A, et al. Among authors: al meslamani az. J Med Econ. 2024 Jan-Dec;27(1):304-308. doi: 10.1080/13696998.2024.2315864. Epub 2024 Feb 22. J Med Econ. 2024. PMID: 38385328 Free article. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

66 results

Search Page